Southborough Firm Lands $6M In Financing
Medical testing specialist SynapDx Corp. of Southborough has secured $6 million in financing from two investors to support development of a gene-based test that can help identify autism-related disorders in children up to 3 years old, the company said.
The money is coming from North Bridge Venture Partners of Waltham and Cambridge-based General Catalyst Partners.
The blood test being developed by SynapDx could speed up diagnoses in children at risk for the disorders and could help them and their parents secure access to the right evaluations and treatment as early as possible, the company said.
"SynapDx has proven that it has the right combination of scientific, clinical and entrepreneurial expertise to develop tests that will offer parents and pediatricians a better, faster way to identify these disorders," said Bill Geary, a partner at North Bridge Venture Partners. "The company's next phase of clinical development will be critical to thousands of children and their families."
"Early treatment of autism has proven to yield better patient outcomes," said Robert Carpenter, a former lead director of Genzyme Corp. who recently joined SynapDx's board of directors. "Initial studies have been promising, and we're looking forward to our next phase of research."
WBJ Web Partners
Most Recent
Most Recent
0 Comments